Atreca, Inc. is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat solid tumors. Atreca’s lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target, engineered from an antibody identified using their discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer tissue samples from multiple patients. The Company has initiated a Phase 1b clinical trial in patients with select solid tumors in which the first patient was dosed in February 2020. Atreca’s efforts beyond ATRC-101 are focused on expanding their clinical pipeline by advancing additional product candidates using their large library of ‘‘hit’’ antibodies that bind preferentially to tumor tissue across patients.